|
KIAA0947 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.18219999958968E-07 |
| Normal-vs-Stage3 |
6.88338275267597E-15 |
| Normal-vs-Stage4 |
6.99440505513849E-15 |
| Stage1-vs-Stage2 |
3.760200E-01 |
| Stage1-vs-Stage3 |
2.039000E-01 |
| Stage1-vs-Stage4 |
7.058500E-03 |
| Stage2-vs-Stage3 |
1.197950E-01 |
| Stage2-vs-Stage4 |
1.628220E-02 |
| Stage3-vs-Stage4 |
1.919640E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.32010000003713E-06 |
| Normal-vs-Asian |
6.56139587107418E-11 |
| Caucasian-vs-AfricanAmerican |
4.741400E-01 |
| Caucasian-vs-Asian |
9.888800E-01 |
| AfricanAmerican-vs-Asian |
4.861600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.555000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(41-60Yrs) |
1.77635683940025E-15 |
| Normal-vs-Age(61-80Yrs) |
1.63080660087189E-12 |
| Normal-vs-Age(81-100Yrs) |
2.164200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.753400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.581000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.867000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.267000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.810800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.774000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.802430E-02 |
| Classical-VS-Follicular |
2.894800E-01 |
| Classical-VS-Other |
1.754360E-01 |
| Classical-VS-Normal |
6.3354987922537E-11 |
| Tall-VS-Follicular |
1.330360E-01 |
| Tall-VS-Other |
8.823400E-01 |
| Tall-VS-Normal |
4.84456919025433E-12 |
| Follicular-VS-Other |
4.201600E-01 |
| Follicular-VS-Normal |
1.1177947456531E-11 |
| Other-VS-Normal |
1.551070E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.99200722162641E-16 |
| Normal-vs-N1 |
3.86468634872017E-13 |
| N0-vs-N1 |
1.182200E-01 |
|
|
